NCT03963817Active, not recruiting
A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)
Snapshot 3D Ultra-high-resolution OCT and Hyperspectral AF of In-vivo Retina
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
This study proposes to use a new instrument (AO-OCT/AF: adaptive optics - optical coherence tomography/autofluorescence) combined with a data processing method to image the retinal pigment epithelium (RPE) of the eye in normal subjects and in subjects with age-related macular degeneration. (AMD). While currently there is no cure, with early diagnosis, vision loss can be slowed. The technology being developed for this project will be the first imaging modality that can provide both structural and molecular information about the retina in vivo and in 3D.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 23 May 2019
- Start date
- 6 Sept 2023
- Primary completion date
- Dec 2027
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Macular degeneration
- NCT number
- NCT03963817
What you commit to
- Study type: Observational
- Planned participants: 50
- From 6 Sept 2023 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to dilation eye drops
Other
- Retinopathy other than AMD.
- Inability to give informed consent
- Bilateral advanced AMD
Who the study is looking for
- Patients must be aged 60 and over and pseudophakic, with clear posterior capsule and dilation to 6mm.
- Patients must be diagnosed early/intermediate AMD in at least one eye (the study eye) with soft drusen or reticular pseudodrusen in the macula.
Age in the registry: 60 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New York Eye and Ear Infirmary of Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.